| Budget Amount *help |
¥16,380,000 (Direct Cost: ¥12,600,000、Indirect Cost: ¥3,780,000)
Fiscal Year 2016: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2015: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2014: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
|
|---|
| Outline of Final Research Achievements |
We demonstrated the followings. Production of 27-OHC was enhanced in the patients with COPD. Treatment with 27-OHC accelerated cellular senescence of lung resident cells and chronic exposure of 27-OHC impaired fibroblast-mediated tissue repair function. Bronchial fibroblasts from COPD patients showed marked pro-fibrotic feature compared to those from control subjects. KLF-5 regulated the profibrotic effects in the cells and expression of KLF-5 was enhanced in the peribronchial lesion of small airways of COPD patients. We demonstrated that production of newly identified anti-oxidants, reactive persulfides species was reduced in the lungs of COPD patients compared with healthy controls. We found that the plasma levels of GDF11, which is an anti-senescent factor, were decreased in COPD patients compared with healthy subjects.
|
